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osting by EAbstract Thalassemia is an inherited blood disorder which is divided into two groups: alpha and
beta.HBA1 andHBA2 are the two genes associated with alpha thalassemia. The aim of this study is
to investigate abnormal hemoglobin variants of alpha globin gene in healthy abnormal hemoglobin
carrying individuals with intact beta globin gene. DNA was extracted from peripheral blood sam-
ples of seven healthy carrier individuals who have abnormal hemoglobin variants and 16 control
individuals from Turkey. Complete coding and intronic sequences of HBA1 and HBA2 genes were
ampliﬁed by polymerase chain reaction (PCR) and PCR products of HBA1 and HBA2 were
sequenced. We were unable to ﬁnd any base change in our carrier group in theHBA1 gene. We have
observed an A/G polymorphism in the downstream untranslated region (+861 G>A) of theHBA2
gene. Our study showed that 14.29% (1/7 carriers) of the carrier group and 37.50% (6/16 controls)
of the control group were heterozygous for the +861 G>A polymorphism. The distribution of
allele frequencies and genotypes of HBA2 between carrier and control samples were analyzed
and it is seen that the distribution of allele frequencies and that of genotypes were not statistically
signiﬁcant between carrier and control samples (P-value = 0.4131, P-value = 0.366, respectively).
HBA2 +861 G>A nucleotide substitution is a neutral polymorphism previously reported in other
populations. This is the ﬁrst report in Turkish population.
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lsevier1. Introduction
Thalassemia is an autosomal recessive genetic blood disorder
that affects a patient’s ability to produce hemoglobin, resulting
in anemia. The disease is common in Mediterranean, Middle
Eastern and Southeast Asian regions [1]. The thalassemias
are classiﬁed according to the type of globin polypeptide chain
that is underproduced. The alpha chain is involved in alpha
thalassemia and the beta chain is affected in beta thalassemia.
Alpha thalassemia is caused by mutations in the alpha chain of
the hemoglobin molecule. There are two carrier states of alpha
Figure 1 PCR ampliﬁcation of HBA1 and HBA2 genes. Lane 1:
100 bp marker, lane 2:HBA1 ampliﬁcation (735 bp), lane 3:HBA2
ampliﬁcation (725 bp), lane 4: non-template control (NTC).
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one gene whereas the second carrier state is characterized by
the loss of two genes producing a condition with small red
blood cells and, at most, a mild anemia. Besides there are
two clinically signiﬁcant forms of alpha thalassemia syndrome
[2,3]. These are Hemoglobin H (HbH) disease and Hb Bart hy-
drops fetalis.
More than 20 different deletional alpha thalassemia muta-
tions and 32 different nondeletional alpha thalassemia muta-
tions which include mutations affecting RNA translation/
processing, mutations in the coding sequences and mutations
in poly A have been reported worldwide [4].
Although alpha thalassemia is rare, more frequently hemo-
globin H disease has been observed in Turkey. The incidence
of alpha thalassemia is about 3% in the C¸ukurova region lo-
cated at the south of Turkey [5–7].
HBA1, the gene encoding hemoglobin alpha 1, and HBA2,
the gene encoding hemoglobin alpha 2, are the two genes asso-
ciated with alpha thalassemia. HBA1 and HBA2 are dupli-
cated and localized to the telomeric region of chromosome
16p within a cluster that includes an embryonic a-like gene
and three pseudogenes. HBA1 and HBA2 consist of three
exons. DNA sequence analysis of human HBA1 and HBA2
shows that their coding sequences are identical. These genes
differ slightly over the 50 untranslated regions and the introns,
but they differ signiﬁcantly over the 30 untranslated regions.
These genes show overall sequence homology >96% [8,9]. Be-
cause of the repetitive nature of this gene cluster, the alpha glo-
bin genes are prone to deletion. Alpha thalassemias result from
deletions of each of the alpha genes as well as deletions of both
of them. Some nondeletional alpha thalassemias have also
been reported [8]. Most of the mutations in alpha globin genes
are deletions and point and regulatory region mutations are
relatively rare.
According to Human Gene Mutation Database (HGMD)
more than 48 different mutations (missense/nonsense, splic-
ing, regulatory, small deletion, small indel, gross deletion
and complex rearrangement) have been reported for the
HBA2 gene and 28 different mutations have been reported
for HBA1 gene for alpha thalassemia phenotype. PCR-based
methods provide a rapid diagnosis and may be used to detect
deletions of the gene HBA1 and HBA2. Sequence analysis
can be used to identify less frequent point mutations or se-
quence variation, in the coding sequences of HBA1 and
HBA2 [10].
Several deletional and nondeletional alpha thalassemia
determinants are present in Turkish populations. Five gene dele-
tions (alpha1 (MED I:17.4 kb, MED II:26.5 and20.5 kb,
alpha 2 (3.7 and 4.2 kb), two different Poly A mutations
(nondeletional alpha thalassemia mutations on HBA2 gene
which are speciﬁc to Mediterranean countries PA1: AA-
TAAAﬁ AATAAG ve PA2: AATAAAﬁ AATGAA), a few
base pair deletion (5 nt (-TGAGG)) on the HBA2 gene andTable 1 Primers designed for the ampliﬁcation HBA1 and HBA2 g
Primer Length of the amplicon Lo
Forward primer HB
Reverse primer 725 bp (from 44th base to 778th base) HB
Reverse primer 735 bp (from 73th base to 798th base) HBa point mutation (Hb Adana, CD 59: GGCﬁ GAC;
Glyﬁ Asp) on the HBA1 gene were reported in Turkey [6,11].
Hb Adana and Poly A (PA2) mutations are ﬁrstly deﬁned in
Turkey [12].
In this study we investigated abnormal hemoglobin variants
of alpha globin gene in healthy abnormal hemoglobin carrying
individuals with intact beta globin gene. For this purpose, we
sequenced alpha globin genes and have found +861 G>A
polymorphism in hemoglobin alpha 2 globin gene.
2. Subjects and methods
Seven healthy abnormal hemoglobin carrier individuals and 16
control individuals were included in this study. None of the
carriers have hemoglobin variant in beta globin gene. Control
individuals are healthy, with normal complete blood count.
Control samples were included in this study to display relation-
ship between the alleles (G and A) and the disease.
Written informed consent is obtained from all the patients
and controls.
DNA was extracted from peripheral blood samples accord-
ing to standard phenol–chloroform protocol. Complete coding
and intronic sequences of HBA1 and HBA2 genes were ampli-
ﬁed by polymerase chain reaction (PCR). The sequences of the
PCR primers are listed in Table 1.
We have ampliﬁed HBA genes as a long single amplicon
(HBA1 725 bp, HBA2 735 bp) using a common forward pri-
mer and gene speciﬁc reverse primer (Fig. 1). We have usedenes.
ci Sequence (50–30) of the primers
A1 and HBA2 CTGTCTCCTGCCGACAAGACC
A1 GGGGGGAGGCCCAAGGGGCAAGAA
A2 GGGAGGCCCAGCGGGCAGGAGGAAC
Table 2 Primers designed for the sequence reaction of HBA1 and HBA2 genes.
Primer Loci Sequence (50–30) of the primers
Nested primer 1F HBA1, HBA2 CCCCAAGCATAAACCCTG
Nested primer 1R HBA1, HBA2 GGGGAAGGACAGGAACATC
Nested primer 2F HBA1, HBA2 AGACTCAGAGAGAACCCACC
Nested primer 2R HBA1, HBA2 GCTCACCTTGAAGTTGACC
Nested primer 3F HBA1, HBA2 ACCACCAAGACCTACTTCC
Nested primer 3R HBA1, HBA2 AACGGTATTTGGAGGTCAG
Nested primer 4F HBA1, HBA2 GGTCAACTTCAAGGTGAGC
Nested primer 4R HBA1 ACTTTATTCAAAGACCACGG
Nested primer 5F HBA1 AGTTCCTGGCTTCTGTGAG
Nested primer 5F/2 HBA2 TCCAAATACCGTTAAGCTG
Nested primer 5R HBA1 GAAAGAGCAAATGCATCCT
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nested primers are listed in Table 2.
PCR products of HBA1 and HBA2 were sequenced using
Beckman DTCS Quick Start Sequencing Kit (Beckman Coul-
ter CEQ 8000 DNA Sequencer, USA) according to the manu-
facturer’s instructions. Sequencing reactions of HBA1 and
HBA2 were carried out using various primers which was given
above. Sequence analysis was performed with SEQUENCHER
(Gene Codes Corporation, USA) sequence analysis software.
The distribution of allele frequencies and genotypes of
HBA2 between carrier and control samples were compared
with Fisher’s exact test. On the other hand, Hardy–Weinberg
equilibrium (HWE) of genotypes frequencies was tested
through Fisher’s exact test since some of the expected counts
are less than 5. All tests were performed by statistical software
R (version 2.10.1). P-values less than 0.05 were considered as
statistically signiﬁcant.
3. Results
In our study, seven healthy abnormal hemoglobin carriers
without any mutation/polymorphism in the beta globin gene
are used as the case group. We have sequenced the alpha
globin genes of these seven individuals and have found +861Figure 2 Electroferogram of the DNA sequence, showing a G to A p
gene.
Table 3 The distribution of +861 G>A HBA2 polymorphism alle
Allele No. of case (%) (n= 7)
G 13 (0.93%)
A 1 (0.07%)G>A polymorphism in hemoglobin alpha 2 globin gene. We
than have screened this polymorphism in 16 healthy individu-
als as the control group.
We were unable to ﬁnd any base change in our carrier
group in the HBA1 gene. The observed polymorphism,
+861 G>A, is located (AGCCTGTGTGTGCCTGGGTTC
TCTCT(A/G)TCCCGGAATGTGCCAACAATGG) in the
downstream untranslated region of the HBA2 gene (Figs. 1
and 2). We have detected this variation only in one out of se-
ven carrier and six out of sixteen control samples.
It is observed that while the frequency of G allele in carrier
and control samples were 0.93% and 0.81%, respectively, the
frequency of A allele was 0.07% in carrier samples and
0.19% in control samples (Table 3). The distribution of G
and A alleles was found to be statistically insigniﬁcant between
carrier and control samples (P-value = 0.4131).
Similarly, our results showed that while six out of seven
healthy carrier individuals genotype was homozygote (GG)
and one carrier’s genotype was heterozygote (AG), the geno-
types of 10 of the 16 control sample individuals were homozy-
gote (GG) and those of six of them were heterozygote (AG)
(Table 4). The distribution of GG and AG genotypes was sta-
tistically insigniﬁcant between carrier and control samples (P-
value = 0.366). The distribution of the genotypes frequenciesolymorphism in the downstream untranslated region of the HBA2
le frequencies in carrier and control samples.
No. of control (%) (n= 16) P-value
26 (0.81%) 0.4131
6 (0.19%)
Table 4 The distribution of +861 G>A HBA2 polymorphism genotypes in carrier and control samples.
Genotype No. of case (%) (n= 7) No. of control (%) (n= 16) P-value
Homozygote (GG) 6 (85.71%) 10 (62.50%) 0.366
Heterozygote (AG) 1 (14.29%) 6 (37.50%)
62 D.C. Dungul et al.was found to be consistent with Hardy–Weinberg equilibrium
(P-value > 0.05).
4. Discussion
Substitutions causing regulatory abnormalities are logged in
with 30 nucleotides ﬂanking the site of the mutation on both
sides known as regulatory mutation (HGMD). Mutations in
Poly A suppress protein synthesis because of the immature
mRNA or decrease protein level due to the short lived mature
mRNA. The location of this substitution we have found is 48
nucleotide relative to poly A signal (+861 G>A).
Lacerra et al. deﬁned this (+861 G>A) variation as a com-
mon nonpathogenic sequence variation 9. Passarello et al.
showed occurrence of the two single point mutations that are
characteristic of Hb Caserta and Hb Sun Prairie, and the
+861 G>A polymorphic site in the homozygous state and
Hb Southern Italy variant, mutation in HBA2 (130 Gﬁ C)
is always associated with another mutation 26 Gﬁ A and with
the polymorphic site HBA2+861 [13,14]. Hb Constant Spring
was conﬁrmed to be associated in cis with the neutral SNP
HBA2 +861 G>A [14]. +861 G>A in HBA2 gene deﬁned
as a common neutral polymorphism in 26 of the 83 Sicilian
individuals [15].
The ratio of single base mutations in regulatory unit is low-
er than splicing, nonsense and missense mutations and higher
than silent and frame shift mutations. Mutations in the 50 UTR
can affect the binding of trans-acting factors that cause incre-
ment or decrement of translation efﬁciency [16,17].
In our study, during screening of abnormal hemoglobin
variants at the HBA2 gene, we detected a previously reported
+861 A>G substitution located 48 nucleotide relative to poly
A signal in HBA2 gene. To conclude, although this neutral
polymorphism was reported in other populations, this is the
ﬁrst report from Turkish population.
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